Neutrophil Functional Disorders


Neutrophils are phagocytes and constitute the most numerous and important effector cells of the innate immune system, especially in the defence against bacteria and fungi. They are rapidly recruited to inflamed tissue in response to inflammatory signals. Egression from the bone marrow and blood stream, adhesion, migration, activation, phagocytosis and killing of pathogens describe the basic mechanisms associated with neutrophils. Neutrophil shortage and functional disorders arise from different rare genetic mutations and can lead to a profound immunodeficiency, often presenting early in life with severe, recurrent and persistent or opportunistic bacterial and fungal infections. An increasing number of such diseases have been identified, especially as whole‐exome sequencing is getting more accessible. This results in better insights in genotypic–phenotypic correlations, susceptibility to specific pathogens and the use of different treatment modalities.

Key Concepts

  • In healthy adults, 1011 neutrophils are generated daily. In steady state, their life span is approximately 1–2 days, which increases up to 3–4 days after neutrophil activation.
  • Certain infections, such as Burkholderia cepacia, Nocardia, Aspergillus nidulans or nontuberculous mycobacteria, should always prompt an inquiry to the possibility of an underlying immune defect.
  • Specific infection locations, such as omphalitis, gingivitis or osteomyelitis, should raise the suspicion of phagocytic cell abnormalities.
  • Abnormal aspects of host response, such as lack of fever, local inflammation or pus, should immediately alert the clinician to the possibility of a neutrophil defect.
  • It is better to perform the right test once than the entire battery of immune defect tests several times. Careful consideration of the clinical and microbiologic presentation usually indicates the right path to pursue.
  • There is no substitute for the right drug, and that requires knowing the pathogen. Because the spectrum of infection in these diseases may range over several microbiologic kingdoms, empiric therapy is to be discouraged in favour of firm diagnoses.
  • A molecular diagnosis should be sought whenever possible. The expanding knowledge of genotype–phenotype relationships suggests that not all defects, even those within the same gene, induce similar clinical symptoms.
  • BCG vaccination should be avoided in individuals with CGD as well as in their newborn close relatives until the defect is ruled out. In general, attenuated viral vaccines are not contraindicated in individuals with primary neutrophil disorders, as antiviral cell‐mediated immunity is intact.

Keywords: neutrophil; leucocyte; immunodeficiency; NADPH oxidase; phagocyte

Figure 1. Interactions of the NADPH oxidase components. The NADPH oxidase consists of a flavocytochrome b558 in the wall of the phagocytic vacuole that transports electrons across the membrane to oxygen, thus producing superoxide. The flavocytochrome consists of two proteins, gp91phox (the beta subunit) and p22phox (the alpha subunit), and is inactive until cytosolic proteins associate with it. These cytosolic proteins are p40phox, p47phox and p67phox and the small GTP‐binding proteins, rac1 or rac2. Activation involves phosphorylation of the phox proteins and the exchange of GDP bound to the rac for GTP. The complex of these cytosolic proteins then translocates to the membrane, where they attach to the flavocytochrome and activate it. The rac acts as a molecular switch and, when the GTP bound to it is hydrolysed to GDP, the system is inactivated. P67phox is tightly associated with p40phox, which is especially involved in NADPH oxidase activity enhancement during phagocytosis. GDI, guanine nucleotide dissociation inhibitor; GDP, guanosine diphosphate; GTP, guanosine triphosphate; NADP, nicotinamide–adenine dinucleotide phosphate; P, phosphate and p21rac, rac1 and rac2.
Figure 2. The genetic basis of chronic granulomatous disease (CGD). The location of genes encoding the components of NADPH oxidase and the frequency of their abnormality in CGD.
Figure 3. CARD9 deficiency. CARD9 in the C‐type lectin pathway, indicating the relevant interactions of the CARD9 protein and the consequences of its deficiency. Both the NFκB‐derived cytokines and the production of cytokines after CD4+ T‐cell stimulation, like Th17 cells and consequently IL‐17, are diminished when CARD9 is absent.


Ambruso DR, McCabe ER, Anderson D, et al. (1985) Infectious and bleeding complications in patients with glycogenosis Ib. American Journal of Diseases of Children 139: 691–697.

Ambruso DR, Knall C, Abell AN, et al. (2000) Human neutrophil immunodeficiency syndrome is associated with an inhibitory Rac2 mutation. Proceedings of the National Academy of Sciences of the United States of America 97: 4654–4659.

Badolato R and Parolini S (2007) Novel insights from adaptor protein 3 complex deficiency. Journal of Allergy and Clinical Immunology 120: 735–741.

Baptista MA, Keszei M, Oliveira M, et al. (2016) Deletion of Wiskott–Aldrich syndrome protein triggers Rac2 activity and increased cross‐presentation by dendritic cells. Nature Communications 7: 12175.

Celmeli F, Oztoprak N, Turkkahraman D, et al. (2016) Successful granulocyte colony‐stimulating factor treatment of relapsing Candida albicans meningoencephalitis caused by CARD9 deficiency. Pediatric Infectious Disease Journal 35: 428–431.

Cole T, McKendrick F, Titman P, et al. (2013) Health related quality of life and emotional health in children with chronic granulomatous disease: a comparison of those managed conservatively with those that have undergone hematopoietic stem cell transplant. Journal of Clinical Immunology 33: 8–13.

Côte M, Ménager MM, Burgess A, et al. (2009) Munc18‐2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. Journal of Clinical Investigation 119: 3765–3773.

Dinauer MC, Nauseef WM and Newburger PE (2001) Inherited disorders of phagocyte killing . In: Seriver CR (ed) The Metabolic and Molecular Bases of Inherited Diseases, pp. 4857–4887. New York: McGraw‐Hill Companies.

Dinauer MC (2014) Disorders of neutrophil function: an overview. Methods in Molecular Biology 1124: 501–515.

Drewniak A, Gazendam RP, Tool AT, et al. (2013) Invasive fungal infection and impaired neutrophil killing in human CARD9 deficiency. Blood 121: 2385–2392.

Flynn R, Grundmann A, Renz P, et al. (2015) CRISPR‐mediated genotypic and phenotypic correction of a chronic granulomatous disease mutation in human iPS cells. Experimental Hematology 43: 838–848.

Fontana S, Parolini S, Vermi W, et al. (2006) Innate immunity defects in Hermansky‐Pudlak type 2 syndrome. Blood 107: 4857–4864.

Gavino C, Cotter A, Lichtenstein D, et al. (2014) CARD9 deficiency and spontaneous central nervous system candidiasis: complete clinical remission with GM‐CSF therapy. Clinical Infectious Diseases 59: 81–84.

Glocker EO, Hennigs A, Nabavi M, et al. (2009) A homozygous CARD9 mutation in a family with susceptibility to fungal infections. New England Journal of Medicine 361: 1727–1735.

Gorlin RJ, Gelb B, Diaz GA, et al. (2000) WHIM syndrome, an autosomal dominant disorder: clinical, hematological, and molecular studies. American Journal of Medical Genetics 91: 368–376.

Güngör T, Teira P, Slatter M, et al. (2014) Reduced‐intensity conditioning and HLA‐matched hematopoietic stem‐cell transplantation in patients with chronic granulomatous disease: a prospective multicenter study. Lancet 383: 436–448.

Hayrapetyan A, Dencher PC, van Leeuwen K, et al. (2013) Different unequal cross‐over events between NCF1 and its pseudogenes in autosomal p47(phox)‐deficient chronic granulomatous disease. Biochimica et Biophysica Acta 1832: 1662–1672.

Hernandez PA, Gorlin RJ, Lukens JN, et al. (2003) Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. Nature Genetics 34: 70–74.

Introne WJ, Westbroek W, Golas GA, et al. (2015) Chediak–Higashi Syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds) GeneReviews® (internet). Seattle: University of Washington; 1993–2017. 2009 Mar 3 [updated 2015 Jan 15].

Kuhns DB, Alvord WG, Heller T, et al. (2010) Residual NADPH oxidase and survival in chronic granulomatous disease. New England Journal of Medicine 363: 2600–2610.

Kuijpers TW, Alders M, Tool ATJ, et al. (2005) Hematologic abnormalities in Shwachman Diamond syndrome: lack of genotype‐phenotype relationship. Blood 106: 356–361.

Kuijpers TW, Tool ATJ, van der Bijl I, et al. (2017) Combined immunodeficiency with severe inflammation and allergy caused by ARPC1B deficiency. Journal of Allergy and Clinical Immunology. pii: S0091‐6749(16)31453‐1. doi: 10.1016/j.jaci.2016.09.061. [Epub ahead of print].

Leiding JW and Holland SM (2016) Chronic Granulomatous Disease. In: Pagon RA, Adam MP, Ardinger HH, et al. (eds) GeneReviews® (internet). Seattle: University of Washington; 1993–2017. 2011, update 11 February.

Lanternier F, Mahdaviani SA, Barbati E, et al. (2015) Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species‐induced meningoencephalitis, colitis, or both. Journal of Allergy and Clinical Immunology 135: 1558–1568.e2.

Lekstrom‐Himes JA, Dorman SE, Kopar P, et al. (1999) Neutrophil‐specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein epsilon. Journal of Experimental Medicine 189: 1847–1852.

Marciano BE, Spalding C, Fitzgerald A, et al. (2015) Common severe infections in chronic granulomatous disease. Clinical Infectious Diseases 60: 1176–1183.

Martire B, Rondelli R, Soresina A, et al. (2008) Clinical features, long‐term follow‐up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clinical Immunology 126: 155–164.

Matute JD, Arias AA, Wright NA, et al. (2009) A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40phox and selective defects in neutrophil NADPH oxidase activity. Blood 114: 3309–3315.

Nunoi H, Yamazaki T, Tsuchiya H, et al. (1999) A heterozygous mutation of beta‐actin associated with neutrophil dysfunction and recurrent infection. Proceedings of the National Academy of Sciences of the United States of America 96: 8693–8698.

Nunoi H, Yamazaki T and Kanegasaki S (2001) Neutrophil cytoskeletal disease. International Journal of Hematology 74: 119–124.

Orelia C and Kuijpers TW (2009) Shwachman–Diamond syndrome neutrophils have altered chemoattractant‐induced F‐actin polymerization and polarization characteristics. Haematologica 94: 409–413.

Picard C and Casanova JL (2004) Inherited disorders of cytokines. Current Opinion in Pediatrics 16: 648–658.

Rieber N, Gazendam RP, Freeman AF, et al. (2016) Extrapulmonary Aspergillus infection in patients with CARD9 deficiency. JCI Insight 1: e89890.

Roberts H, White P, Dias I, et al. (2016) Characterization of neutrophil function in Papillon–Lefèvre syndrome. Journal of Leukocyte Biology 100: 433–444.

Roos D and de Boer M (2014) Molecular diagnosis of chronic granulomatous disease. Clinical and Experimental Immunology 175: 139–149.

Schmidt S, Moser M and Sperandio M (2013) The molecular basis of leukocyte recruitment and its deficiencies. Molecular Immunology. 55: 49–58.

Schymeinsky J, Mócsai A and Walzog B (2007) Neutrophil activation via β2 integrins (CD11/CD18):Molecular mechanisms and clinical implications. Thrombosis and Hemostasis 98: 262–273.

Segal BH, Leto TL, Gallin JI, et al. (2000) Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 79: 170–200.

Svensson L, Howarth K, McDowall A, et al. (2009) Leukocyte adhesion deficiency‐III is caused by mutations in KINDLIN3 affecting integrin activation. Nature Medicine 15: 306–312.

The International Chronic Granulomatous Disease Cooperative Study Group (1991) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. New England Journal of Medicine 324: 509–516.

Uzel G, Tng E, Rosenzweig SD, et al. (2008) Reversion mutations in patients with leukocyte adhesion deficiency type‐1 (LAD‐1). Blood 111: 209–218.

Uzzan M, Ko HM, Mehandru S, et al. (2016) Gastrointestinal disorders associated with common variable immune deficiency (CVID) and Chronic Granulomatous Disease (CGD). Current Gastroenterology Reports 18: 17.

van de Vijver E, Maddalena A, Sanal Ö, et al. (2012) Hematologically important mutations: leukocyte adhesion deficiency (first update). Blood Cells, Molecules & Diseases 48: 53–61.

Winkelstein JA, Marino MC, Johnston RB, et al. (2000) Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 79: 155–169.

Zhao XW, Gazendam RP, Drewniak A, et al. (2013) Defects in neutrophil granule mobilization and bactericidal activity in familial hemophagocytic lymphohistiocytosis type 5 (FHL‐5) syndrome caused by STXBP2/Munc18‐2 mutations. Blood 122: 109–111.

van Zwieten R, Verhoeven AJ and Roos D (2014) Inborn defects in the antioxidant systems of human red blood cells. Free Radical Biology and Medicine 67: 377–386.

Further Reading

Dinauer MC (2016) Primary immune deficiencies with defects in neutrophil function. Hematology. American Society of Hematology. Education Program 2016: 43–50.

Nauseef WM (2016) Neutrophils, from cradle to grave and beyond. Immunological Reviews 273: 5–10.

Wang G and Nauseef WM (2015) Salt, chloride, bleach, and innate host defense. Journal of Leukocyte Biology 98: 163–172.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
van de Geer, Annemarie, Gazendam, Roel P, Kuijpers, Taco W, and Roos, Dirk(Jun 2017) Neutrophil Functional Disorders. In: eLS. John Wiley & Sons Ltd, Chichester. [doi: 10.1002/9780470015902.a0002182.pub3]